Drug intelligence / Profile preview

CT-03 (Celestial Therapeutics)

Development stage: Preclinical
Lead developer: Celestial Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

CT-03 is a preclinical mRNA vaccine candidate developed by Celestial Therapeutics for the prevention of Chikungunya virus infection. It is built upon the company's proprietary Stellar-mRNA platform, which is characterized as a self-adjuvanting technology. This platform is designed to enhance vaccine efficacy while significantly reducing reactogenicity, potentially allowing for effective immunization at very low doses compared to traditional mRNA technologies. Celestial Therapeutics, a California-based biotechnology company and resident of Johnson & Johnson Innovations-JLABS, is currently advancing CT-03 through preclinical development.

Other names: CT-03-Celestial Therapeutics-mRNACT03-Celestial Therapeutics-mRNACT 03-Celestial Therapeutics-mRNA

Beyond the preview

Go deeper on CT-03 (Celestial Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-03 (Celestial Therapeutics).

Explore the full profile